🧠 Mirae Asset Healthcare Fund Direct – Growth

• Benchmark: BSE Healthcare TRI

• AUM: ~₹2,800–₹2,900 Cr

• NAV: ~₹44–45

• Expense Ratio: ~0.47%

• Fund Manager: Ankit Jain (long tenure across healthcare sleeve)

• Inception: Jun 2018

🏆 SBI Healthcare Opportunities Fund Direct – Growth

• Benchmark: BSE Healthcare TRI

• AUM: ~₹4,000+ Cr

• Expense Ratio: ~0.85–0.95%

• Fund Manager: Dinesh Balachandran

• Legacy: One of the oldest healthcare strategies in India

⚡ Nippon India Pharma Fund Direct – Growth

• Benchmark: BSE Healthcare TRI

• AUM: ~₹8,000+ Cr (category leader)

• Expense Ratio: ~0.85–0.95%

• Fund Manager: Sailesh Raj Bhan

• Style: Pure pharma, high-conviction

🧊 ICICI Prudential Nifty Pharma Index Fund Direct – Growth

• Benchmark: Nifty Pharma TRI

• AUM: ~₹100–150 Cr

• Expense Ratio: ~0.8–1.0%

• Style: Passive replication

📊 2) Performance Matrix (CAGR — Validated Bands)

👉 Observation:
Point-to-point returns converge—but path (volatility + drawdowns) diverges sharply.

🧪 3) Risk Analytics

Interpretation

• SBI → Best risk-adjusted (higher Sharpe, lower beta)

• Mirae → Efficient alpha (slightly higher risk, better cost)

• Nippon → High beta (amplifies cycles)

• ICICI → Mirrors market risk (no alpha cushion)

📂 4) Portfolio Construction

🧠 Mirae Healthcare

• Top Holdings: Sun Pharma (~12%), Divi’s (~8%), Apollo Hospitals (~7%)

• Sub-sector mix: Pharma (~60%), Hospitals (~20%), CRAMS/Diagnostics (~20%)

• Market cap: Large (65%) | Mid (25%) | Small (10%)

👉 Balanced healthcare exposure = smoother outcomes

🏆 SBI Healthcare

• Diversified across pharma + hospitals + niche manufacturing

• More even weight distribution → lower concentration risk

⚡ Nippon Pharma

• ~90–100% pharma allocation

• Heavy weights in large pharma exporters

👉 Pure cycle play (USFDA + exports + pricing cycles)

🧊 ICICI Pharma Index

• Replicates Nifty Pharma constituents

• No active allocation decisions

📉 5) Rolling Return Consistency (10-Year Framework)

👉 Key takeaway:

• SBI = highest reliability

• Nippon = highest dispersion (timing sensitive)

📉 6) Probability Model (5Y Rolling >15%)

👉 This is the real edge metric:

• Not “what returns are possible”

• But how often they actually occur

📉 7) Drawdown Case Studies

🦠 COVID Crash (2020)

• Nippon: Sharp fall → fastest rebound

• SBI: Controlled fall → smoother recovery

• Mirae: Moderate fall → balanced recovery

📉 Pharma Downcycle (2022)

• Nippon: Underperformed most

• SBI/Mirae: Better protected due to diversification

💰 8) Cost Impact (10-Year Compounding)

• Mirae: ~0.47%

• Others: ~0.9%

👉 On ₹10L over 10 years:

• Cost difference can add ₹1.5–₹2L extra corpus

👉 This is structural alpha, not market-driven

📊 9) SIP vs Lump Sum Analysis

SIP Investors

• SBI → Highest success probability

• Mirae → Strong long-term alpha

• Nippon → Works only if cycle captured

Lump Sum Investors

• Entry timing becomes critical

• Nippon = high risk of wrong entry

🎯 10) Suitability Matrix

🏆 FINAL RANKING

🥇 SBI Healthcare Opportunities Fund - 👉 Best risk-adjusted + consistency leader

🥈 Mirae Asset Healthcare Fund -  👉 Best cost-efficient alpha generator

🥉 Nippon India Pharma Fund - 👉 Best high-beta tactical play

🧊 ICICI Pharma Index - 👉 Best passive exposure

🧠 FINAL INVESTMENT FRAMEWORK

Recommended Allocation Model

• SBI Healthcare → 50–60% (Core stability engine)

• Mirae Healthcare → 25–30% (Alpha layer)

• Nippon Pharma → 10–15% (Cycle kicker)

🔥 Closing Insight

In sector funds, returns are cyclical—but probability is structural.

• SBI wins on probability

• Mirae wins on efficiency

• Nippon wins on timing

⚠️ Disclaimer

• Sector funds carry very high risk

• Allocation should not exceed 10–15% of total portfolio

• Data ranges are based on latest available factsheets and category analytics; investors should verify with latest AMC disclosures before investing.